One-Month Duration Compared with Twelve-Month Duration of Dual Antiplatelet Therapy in Elective Angioplasty for Coronary Artery Disease: Bleeding and Ischaemic Outcomes
Authors:
- Natasha CorballisNCNatasha Corballis
- U. BhalraamUBU. Bhalraam
- Ioannis MerinopoulosIMIoannis Merinopoulos
- Tharusha GunawardenaTGTharusha Gunawardena
- Vasiliki TsampasianVTVasiliki Tsampasian
- Upul WickramarachchiUWUpul Wickramarachchi
- Simon EccleshallSESimon Eccleshall
- Vassilios S. VassiliouVVVassilios S. Vassiliou
Open Access
- 2 August 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (15) , 4521
Abstract
Background/Objectives: The need to determine the safest duration of dual antiplatelet therapy duration after elective angioplasty to reduce bleeding events without an adverse effect on major adverse cardiovascular events (MACE) remains a challenge. Methods: In this investigator-initiated, single-centre cohort study, we identified all patients who underwent PCI for de novo coronary disease for stable angina between January 2015 and November 2019. We compared 1-month and 12-month durations of dual antiplatelet therapy (DAPT) to determine if there was any difference in the primary outcome of major bleeding. The secondary outcome was a patient-oriented composite endpoint of all-cause mortality; any myocardial infarction, stroke, or revascularisation; and the individual components of this composite endpoint. Data were analysed using Cox regression models and cumulative hazard plots. Results: A total of 1025 patients were analysed, of which 340 received 1 month of DAPT and 685 received 12 months of DAPT. There was no difference in major bleeding between the two groups (2.6% vs. 2.5% respectively). On univariable cox regression analysis, no characteristics were predictors of major bleeding. A proportion of 99.7% of patients in the 1-month DAPT arm were treated with a DCB strategy, whilst 93% in the 12-month DAPT group were treated with a DES. There was no difference between the two groups with regards to the composite patient-oriented MACE (11% vs. 12%, respectively) or any individual component of this. These results were unchanged after propensity score matched analysis. Conclusions: A 1-month duration of DAPT, for which 99.7% of patients were treated with a DCB strategy, appears safe and effective when compared with a 12-month duration of DAPT with no difference in major bleeding or MACE.Keywords
This publication has 36 references indexed in Scilit:
- Myocardial inflammation after elective percutaneous coronary interventionHellenic Journal of Cardiology, 2024
- P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting StentJAMA Network Open, 2024
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary DiseaseJACC, 2023
- Paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease in elective clinical practiceClinical Research in Cardiology, 2022
- 1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent ImplantationJACC: Cardiovascular Interventions, 2021
- Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: A systematic review and meta‐analysisCatheterization and Cardiovascular Interventions, 2020
- Long-term safety of paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease: the SPARTAN DCB studyClinical Research in Cardiology, 2020
- Duration of dual antiplatelet therapy in elective drug‐coated balloon angioplastyCatheterization and Cardiovascular Interventions, 2019
- Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial InfarctionJACC: Cardiovascular Interventions, 2019
- Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent CandidatesJACC, 2015